GGrantIndex
← Leaderboards

Owen N Witte

University Of California Los Angeles

$15,146,055
Attributed
$24,727,903
Total exposure
13
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.1M · FY200723
$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$24,727,903 · 13

By mechanism

U01$7,089,679 · 2
R01$7,051,745 · 3
T32$5,138,322 · 2
P50$4,292,890 · 5
U54$1,155,267 · 1

Top collaborators

Most similar at University Of California Los Angeles

Same institution · by research overlap

Others in their field

Top investigators on “Malignant Neoplasm Of Prostate

Research focus

Malignant Neoplasm Of ProstateTumorMalignant NeoplasmsCellsTissuesProstateProgramsPhenotypeOncogenesResponseSpecificityResistanceImmunotherapyTargeted TreatmentProteinsAdvanced DiseaseCancer CellEventAndrogensStem CellsCastration Resistant Prostate CancerMediatingPathway InteractionsSignal Transduction

Grant awards (54)

Tumor Cell Biology Training Program$480,906
T32 · FY2023 · CA
Project 3: Developing CAR T Cell Therapies to Target Tumor Heterogeneity in Advanced Prostate Cancer$327,804
P50 · FY2023 · CA · contact PI
Targeting alternative splicing for TCR discovery in small cell carcinomas$779,998
U01 · FY2022 · CA · contact PI
Multi-omic analysis of Myc-driven splicing for prostate cancer therapeutic development$634,446
R01 · FY2022 · CA · contact PI
Targeting Genomic Instability in Lethal Neuroendocrine Prostate Cancer$519,628
R01 · FY2022 · CA
Project 3: Developing CAR T Cell Therapies to Target Tumor Heterogeneity in Advanced Prostate Cancer$336,009
P50 · FY2022 · CA · contact PI
Targeting alternative splicing for TCR discovery in small cell carcinomas$779,998
U01 · FY2021 · CA · contact PI
Multi-omic analysis of Myc-driven splicing for prostate cancer therapeutic development$647,398
R01 · FY2021 · CA · contact PI
Targeting Genomic Instability in Lethal Neuroendocrine Prostate Cancer$530,232
R01 · FY2021 · CA
Tumor Cell Biology Training Program$522,696
T32 · FY2021 · CA
Project 3: Developing CAR T Cell Therapies to Target Tumor Heterogeneity in Advanced Prostate Cancer$327,804
P50 · FY2021 · CA · contact PI
Targeting alternative splicing for TCR discovery in small cell carcinomas$250,000
U01 · FY2021 · CA · contact PI
Targeting alternative splicing for TCR discovery in small cell carcinomas$779,998
U01 · FY2020 · CA · contact PI
Multi-omic analysis of Myc-driven splicing for prostate cancer therapeutic development$647,398
R01 · FY2020 · CA · contact PI
Targeting Genomic Instability in Lethal Neuroendocrine Prostate Cancer$530,232
R01 · FY2020 · CA
Tumor Cell Biology Training Program$511,197
T32 · FY2020 · CA
Project 3: Developing CAR T Cell Therapies to Target Tumor Heterogeneity in Advanced Prostate Cancer$271,267
P50 · FY2020 · CA · contact PI
Targeting alternative splicing for TCR discovery in small cell carcinomas$779,998
U01 · FY2019 · CA · contact PI
Multi-omic analysis of Myc-driven splicing for prostate cancer therapeutic development$627,973
R01 · FY2019 · CA · contact PI
Targeting Genomic Instability in Lethal Neuroendocrine Prostate Cancer$514,324
R01 · FY2019 · CA
Tumor Cell Biology Training Program$470,139
T32 · FY2019 · CA
Project 3: Developing CAR T Cell Therapies to Target Tumor Heterogeneity in Advanced Prostate Cancer$357,342
P50 · FY2019 · CA · contact PI
Targeting alternative splicing for TCR discovery in small cell carcinomas$779,998
U01 · FY2018 · CA · contact PI
Multi-omic analysis of Myc-driven splicing for prostate cancer therapeutic development$646,360
R01 · FY2018 · CA · contact PI
Targeting Genomic Instability in Lethal Neuroendocrine Prostate Cancer$529,948
R01 · FY2018 · CA
Tumor Cell Biology Training Program$432,898
T32 · FY2018 · CA
Evaluating a Novel Strategy to Target Trop2 in Prostate Cancer$174,377
P50 · FY2018 · CA · contact PI
Tumor Cell Biology Training Program$397,157
T32 · FY2017 · CA
Evaluating a Novel Strategy to Target Trop2 in Prostate Cancer$263,817
P50 · FY2017 · CA · contact PI
Evaluating a Novel Strategy to Target Trop2 in Prostate Cancer$247,450
P50 · FY2016 · CA · contact PI
Influences of the Microenvironment on Cancer Stem Cells$593,215
U01 · FY2015 · CA · contact PI
Evaluating a Novel Strategy to Target Trop2 in Prostate Cancer$251,929
P50 · FY2015 · CA · contact PI
Influences of the Microenvironment on Cancer Stem Cells$579,004
U01 · FY2014 · CA
Evaluating a Novel Strategy to Target Trop2 in Prostate Cancer$247,308
P50 · FY2014 · CA · contact PI
Influences of the Microenvironment on Cancer Stem Cells$544,406
U01 · FY2013 · CA
Evaluating a Novel Strategy to Target Trop2 in Prostate Cancer$245,344
P50 · FY2013 · CA · contact PI
Influences of the Microenvironment on Cancer Stem Cells$600,277
U01 · FY2012 · CA
Influences of the Microenvironment on Cancer Stem Cells$622,787
U01 · FY2011 · CA
Developmental Research Program$241,869
P50 · FY2011 · CA · contact PI
Developmental Research Program$254,599
P50 · FY2010 · CA · contact PI
MICRO/NANO-IMMUNOCHIP (UIC) DEVELOPMENT AND TESTING IN MICE AND HUMANS$639,099
U54 · FY2009 · CA · contact PI
Developmental Research Program$254,539
P50 · FY2009 · CA · contact PI
MICRO/NANO-IMMUNOCHIP (UIC) DEVELOPMENT AND TESTING IN MICE AND HUMANS$516,168
U54 · FY2008 · CA · contact PI
Developmental Research Program$254,497
P50 · FY2008 · CA · contact PI
Developmental Research Program$236,935
P50 · FY2007 · CA · contact PI
Medical Scientist Training Program$1,176,426
T32 · FY2004 · GM
Medical Scientist Training Program$1,146,903
T32 · FY2003 · GM
ABL ONCOGENE AND MURINE AND HUMAN LEUKEMIAS$420,051
R01 · FY2002 · CA
Measuring anti-tumor cell mediated immunity by PET$0
P50 · FY2002 · CA
Measuring anti-tumor cell mediated immunity by PET$0
P50 · FY2002 · CA
ABL ONCOGENE AND MURINE AND HUMAN LEUKEMIAS$407,817
R01 · FY2001 · CA
Measuring anti-tumor cell mediated immunity by PET$0
P50 · FY2001 · CA
ABL ONCOGENE AND MURINE AND HUMAN LEUKEMIAS$395,938
R01 · FY2000 · CA
Measuring anti-tumor cell mediated immunity by PET$0
P50 · FY2000 · CA